Lortab falls under the category of opioids, which are known to carry potential risks to the developing fetus. Hydrocodone, one of the key components in Lortab, can cross the placenta, which may lead to withdrawal symptoms in newborns if taken frequently or at high doses during pregnancy. The U.S. Food and Drug Administration (FDA) classifies Lortab as a Category C drug, meaning that the potential risks to the fetus cannot be ruled out.
